<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681785</url>
  </required_header>
  <id_info>
    <org_study_id>269/05</org_study_id>
    <nct_id>NCT00681785</nct_id>
  </id_info>
  <brief_title>Thrombophylaxis in Transurethral Surgery With Dalteparine</brief_title>
  <official_title>Thromboseprophylaxe Mit Niedermolekularem Heparin Bei Transurethralen Eingriffen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for thrombophrophylaxis is well known. Without prophylaxis the incidence of
      objectivlely confirmed, hospital-acquired deep venous thrombosis is approximately 10% to 40%
      among medical or general surgical patients. In urology the prevalence is 15-40%. The Seventh
      ACCP Conference on Antithrombotic and Thrombolytic Therapy1 recommend against specific
      prophylaxis in patients undergoing transurethral procedures. Our study is the first
      double-blind, placebo-controlled study with Dalteparine as thrombophrophylaxis in
      transurethral surgery. The aim of the study is to proof that thrombophrophylaxis causes not
      more complications in transurethral surgery than without.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of our study is to proof that transurethral surgery under thrombophylaxis with
      dalteparine is safe. The study design is double-blind placebo controlled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>intraoperativ, 6 hours post op and 3 days postop</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Thrombophylaxis in Transurethral Surgery</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5000IE dalteparine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCL 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalteparine (Fragmin)</intervention_name>
    <description>transurethrals surgery with and without dalteparine</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Dlateparine=Fragmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  transurethral surgery

        Exclusion Criteria:

          -  oral anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C Gasser, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Urology Liestal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urologische Universit√§tsklinik beider Basel</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <last_update_submitted>May 19, 2008</last_update_submitted>
  <last_update_submitted_qc>May 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Maurer Patrick, Dr</name_title>
    <organization>Department of Urology, Kantonsspital Liestal</organization>
  </responsible_party>
  <keyword>thrombophylaxis and transurethral surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

